Request a Meeting
contact mi

Nuvaira is a privately held medical device company headquartered in Minneapolis MN (USA) that develops therapies to improve outcomes for patients suffering from obstructive lung diseases by addressing underlying disease pathophysiology.  Targeted Lung Denervation (TLD) is a novel bronchoscopic procedure that disrupts parasympathetic pulmonary nerve input to the lung to reduce the clinical consequences of neural hyperactivity.  Mechanistically similar to anticholinergics, the one-time TLD procedure may durably reduce acetylcholine release, and thus has the potential to reduce exacerbation risk, improve symptoms, and stabilize lung function. Nuvaira is enrolling patients in AIRFLOW-3, a pivotal trial with the goal of improving clinical stability and reducing exacerbations in moderate-to-severe Group “D” COPD patients. Visit www.nuvaira.com or www.airflowtrial.com

COPD Exacerbations are the Problem.
Be Part of the Solution.
Please contact us to learn where you can refer patients for the AIRFLOW-3 Clinical Trial.


product resources
video library